Home > Resources > Whitepapers > Five Ways to Streamline Building Manufacturing Systems for Biotech and Pharmaceutical Industries

Five Ways to Streamline Building Manufacturing Systems for Biotech and Pharmaceutical Industries

May 12, 2016

Today’s biotech and pharmaceutical production facilities must drive faster times to market and greater profitability for new products by boosting production yields and accelerating commercialization and scaling of capacityRising healthcare demand worldwide is driving the need for expanded manufacturing capacity in the biotech and pharmaceutical industries. Aging populations. Soaring rates of chronic lifestyle diseases. Emerging middle-classes in developing nations. Treatment and technology advancements. All of these are factors some analysts expect to keep life sciences industries growing faster than the world’s GDP in years to come.

Spotlight

mAbxience

A global biopharmaceutical company specialized in research, development and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

OTHER WHITEPAPERS

Biotech Talent Management

whitePaper | February 2, 2022

While many sectors were dealt a severe blow by the COVID-19pandemic, biotech and medtech saw continued growth andare thus attracting top candidates even for non-scientific roles.

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

Valorization of Starch to Biobased Materials

whitePaper | May 30, 2022

Many concerns are being expressed about the biodegradability, biocompatibility, and longterm viability of polymer-based substances. This prompted the quest for an alternative source of material that could be utilized for various purposes.

Cell and Gene Therapy Hot Buttons Series

whitePaper | September 27, 2022

Cell and Gene Therapy (CAGT) activity has increased dramatically in recent decades, especially in Chimeric Antigen Receptor T-Cell (CAR-T) clinical trials and therapy registrations. The IQVIA CAGT Hot Buttons series covers basic concepts in CAGT for newcomers to this field.

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.